RipeTime is financially supported by a well-known group of visionary seed and angel investors who see the commercial opportunities presented by our game-changing technology.

Our capital advisory partners, Gilligan Sheppard, have succeeded in raising over $2 million in the first year of operation, enabling us to rapidly move to a cost-sharing proof of concept phase with key partners in the produce industry.

Support from the New Zealand Venture Investment Fund, New Zealand Trade & Enterprise and the Callaghan Innovation Growth Grant has proven invaluable, in terms not only of execution support, but advice and guidance as we have moved into new markets.

In one year RipeTime has moved from concept to proof in a number of vertical markets, has completed trials in NZ and is poised to carry out further exercises in Australia and North America. It is actively engaged in discussions to form strategic partnerships to leverage existing global distribution networks with established industry players, and is negotiating joint venture arrangements to licence its technology into segments that have been identified as non-core.

The key to RipeTimes’ success is the patented ability to detect molecules at well below 10 parts per billion in the atmosphere – at box/tray level and in Cool-stores, in shipping containers, and on-board ships. RipeTime continues to make progress both in terms of R&D, commercialization and market development. The board expects this to continue, and is pleased to enjoy the support of the existing shareholder group.

We are always interested in hearing from prospective investors in the agri-tech sector, or industries that see opportunities to strategically partner to leverage our extraordinarily sensitive technology in other sectors.

Our current capital round closes in October 2017: qualified investors can request a copy of our information memorandum through our capital partners, Gilligan Sheppard:

Our investors can be found here